Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 124-129

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.124129

Advances in Bioresearch

REVIEW ARTICLE

Comprehensive Review of Regenerative Medicine in Orthopaedics: Current State and Future Perspectives

Ravindra B. Gunaki, Santosh Takale, Anupam Kolekar, Shivaji Avate
Department of Orthopaedics Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

ABSTRACT

In orthopaedics, regenerative medicine has become a game-changer, transforming treatment modalities via its emphasis on tissue regeneration, repair, and functional restoration. This study offers a comprehensive examination of the state of regenerative orthopaedics now and its possibilities for the future. It covers a wide range of modalities, including tissue engineering, growth factor treatments, stem cell therapies, and their clinical applications. Mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) are two examples of stem cell-based treatments that show great promise for tissue-specific regeneration, especially when it comes to treating osteoarthritis and cartilage abnormalities. Bone morphogenetic proteins (BMPs) and platelet-rich plasma (PRP) are two examples of growth factor therapies that are effective at accelerating bone production and improving tendon repair. Furthermore, biomimetic scaffold-based tissue engineering techniques have intriguing answers for reconstructing bone defects and regaining musculoskeletal integrity. Widespread clinical translation is hampered, meanwhile, by issues with treatment standardisation, long-term safety, ethical issues, and regulatory frameworks. The ethical landscape of the discipline is further complicated by ethical conundrums pertaining to patient access and cell source. To advance regenerative orthopaedics, it is critical to address the economic consequences, harmonise worldwide regulatory standards, and promote multidisciplinary cooperation. Future orthopaedic care might be revolutionised by combining artificial intelligence (AI), personalised medicine, and improved biomaterials, with a focus on patient-centered care and precision therapies. This thorough analysis highlights the field's transformational potential and points out important obstacles as well as future directions for research and development.

Keywords*: Regenerative medicine, Orthopedics, Stem cell therapy, Tissue engineering, Growth factors.*

Received 24.11.2023 Revised 01.12.2023 Accepted 21.03.2024

How to cite this article:
Ravindra B. G, Santosh T, Anupam K, Shivaji A. Comprehensive Review of Regenerative Medicine in Orthopedics: Current State and Future Perspectives. Adv. Biores., Vol 15 (2) March 2024: 124-129

INTRODUCTION

In orthopaedics, regenerative medicine has become a game-changer, transforming treatment modalities via its emphasis on tissue regeneration, repair, and functional restoration. Conventional orthopaedic treatments frequently focus on symptom relief or tissue repair rather than full regeneration, which can lead to long-term impairments and poor patient outcomes. Regenerative medicine, on the other hand, offers cutting-edge techniques that use the body's natural healing abilities with the goal of restoring tissue integrity and function in addition to symptom relief.

Developments in tissue engineering methods, growth factor treatments, and stem cell therapies have driven this paradigm change in orthopaedic therapy [1]. The capacity of stem cells to develop into diverse cell types makes them extremely promising for the regeneration of musculoskeletal tissues, such as cartilage and bone [2]. Moreover, growth factors that modulate tissue repair and regeneration include platelet-rich plasma (PRP) and bone morphogenetic proteins (BMPs) [3]. Because these treatment techniques may activate the body's natural healing processes, they have attracted a lot of interest and provide potential directions for orthopaedic applications.

A wide range of ailments are included in the category of orthopaedic disorders, from catastrophic injuries to degenerative illnesses like osteoarthritis and osteoporosis. Regenerative medicine has several applications in treating these many musculoskeletal conditions, and it has great potential [4]. Stem cell-based treatments have shown promise in repairing articular cartilage abnormalities, with the goal of

halting the progression of osteoarthritis and restoring joint functioning [5]. Furthermore, it has been demonstrated that growth factor therapies, in particular PRP injections, are effective in lowering pain and accelerating tendon repair in disorders such as tendinopathies and rotator cuff injuries [6].

Another essential component of regenerative medicine is tissue engineering, which entails creating biomimetic scaffolds to imitate the original tissue milieu and promote tissue regeneration and cell proliferation [7]. Large bone defects from trauma or tumour resections are among the important orthopaedic difficulties that these synthetic structures hold enormous promise to solve. Tissue-engineered scaffolds present a potential approach to bone defect rebuilding and healing by offering a supporting framework for cell proliferation and differentiation [8].

Notwithstanding the noteworthy advancements in the field of regenerative orthopaedics, some obstacles and constraints continue to impede the broad clinical use of these inventive methodologies. Protocol and procedure standardisation is still a major problem [9]. It might be difficult to guarantee repeatability and consistency of results when there is variation in cell source, isolation techniques, and administration regimens. Furthermore, thorough preclinical and clinical research is needed to guarantee the long-term safety and effectiveness of these therapies [10].

An important factor in the use of regenerative medicine in orthopaedics is ethical issues. Careful consideration must be given to issues pertaining to the moral procurement of cells, informed patient consent, and fair distribution of these cutting-edge treatments [11]. Furthermore, patients from a variety of socioeconomic situations may find these novel therapies to be inaccessible or unaffordable due to their high costs [12].

The approval, production, and clinical use of regenerative orthopaedic medicines are subject to regulatory regimes that pose certain hurdles. To ensure patient safety and efficacy, current regulatory routes must be modified to account for the special characteristics of these treatments [13]. Collaboration between regulatory organisations, researchers, and industry stakeholders is necessary to address the huge problem of harmonising regulatory norms internationally while promoting innovation [14].

Section 1: Overview of Regenerative Medicine in Orthopaedics

Regenerative medicine offers a multimodal approach to tissue regeneration and repair, which is a paradigm change in orthopaedics. An extensive summary of the many modalities included in regenerative medicine and their uses in orthopaedic therapy is given in this section.

Regenerative orthopaedics relies heavily on stem cell-based treatments, which use the special abilities of stem cells to promote tissue regeneration and repair [1]. Because of their ability to develop into multiple musculoskeletal lineages, such as osteoblasts, chondrocytes, and tenocytes, mesenchymal stem cells (MSCs) hold great promise [2]. Because of their pluripotency, MSCs are a desirable option for treating a variety of orthopaedic issues, such as cartilage damage and bone abnormalities. Furthermore, a major element in the therapeutic effectiveness of MSCs is their paracrine actions, which occur when they produce bioactive substances that promote tissue regeneration [3]. According to recent research, MSCs may help regenerate cartilage, reduce inflammation, and alter the microenvironment in osteoarthritic joints, which may lead to the development of innovative treatment approaches [4].

Apart from mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs) have become a game-changing technique in orthopaedic regeneration treatments. iPSCs—somatic cells that have been reprogrammed to become pluripotent—have enormous promise for personalised medicine because they can provide patient-specific cell sources for tissue regeneration [5]. The relevance of induced pluripotent stem cells (iPSCs) in the area of regenerative orthopaedics is highlighted by their ability to differentiate into many cell types that are essential for musculoskeletal regeneration. Additionally, iPSCs pose less ethical difficulties than embryonic stem cells. However, before being used in clinical settings, thorough preclinical testing is required because to concerns about both their safety and carcinogenic potential.

Furthermore, it is impossible to exaggerate the significance of growth factors in the coordination of tissue regeneration and repair in orthopaedics. Growth factors are essential for controlling cell division, proliferation, and the production of extracellular matrix. Examples of these factors are fibroblast growth factor (FGF), insulin-like growth factor (IGF), and transforming growth factor-beta (TGF-β) [7]. A subset of the TGF-β superfamily, bone morphogenetic proteins (BMPs), have become well-known for their ability to stimulate osteogenesis and improve bone repair [8]. BMPs have been used clinically in spinal fusion surgeries and non-union fracture care, where they promote bone production and quicken healing to lessen the requirement for autologous bone transplants and their related side effects [9].

Another option for growth factor-based orthopaedic treatments is platelet-rich plasma (PRP), which is a concentration of autologous platelets in plasma. Many growth hormones and cytokines, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are involved

in angiogenesis and tissue regeneration, are present in platelet-derived platelet plasma (PRP) [10]. PRP has been shown in clinical trials to be effective in treating a range of orthopaedic disorders, such as tendinopathies, osteoarthritis, and ligament injuries. These studies have also demonstrated PRP's capacity to promote tissue regeneration and lessen pain [11]. PRP's repeatability and clinical results are still affected by differences in its composition and the standardisation of PRP production techniques, which are still causes for worry.

To sum up, the overview of regenerative medicine in orthopaedics covers a wide range of techniques, including as growth factor treatments and stem cell-based therapies, and their many uses in tissue regeneration and repair. Growth factors like BMPs and PRP show promise in regulating tissue repair and function, while stem cells, particularly MSCs and iPSCs, provide flexible platforms for tissue-specific regeneration. These novel approaches have the potential to significantly transform orthopaedic treatment, but their effective clinical use will require more study and rigorous assessment.

Section 2: Clinical Applications of Regenerative Medicine in Orthopedics

Regenerative medicine is being used in orthopaedics to treat a wide range of musculoskeletal disorders. These applications provide novel ways to treat degenerative illnesses and crippling injuries.

Osteoarthritis (OA), a common degenerative joint disease marked by cartilage degradation and joint inflammation, is one of the primary conditions for which regenerative orthopaedics has demonstrated encouraging results [5]. Mesenchymal stem cells (MSCs), in particular, have shown promise in stem cell treatments for increasing cartilage repair and delaying the onset of osteoarthritis (OA) [6]. Studies investigating the intra-articular injection of MSCs in patients with osteoarthritis (OA) have shown improvements in cartilage regeneration, joint function, and pain reduction [7]. This presents a potential treatment approach for this difficult disease.

Furthermore, there has been a lot of interest in orthopaedic practice on the use of regenerative techniques to treat ligament and tendon injuries. Achilles tendon ruptures and rotator cuff tears are examples of tendon injuries that provide difficulties because of their poor intrinsic healing potential. Growth factor-based therapies, such as injections of platelet-rich plasma (PRP), have shown promise as adjuvants to improve tendon healing and clinical outcomes [8]. PRP, which is abundant in cytokines and growth factors, promotes extracellular matrix formation and cellular proliferation to improve tendon repair and expedite the healing process.

Furthermore, regeneration methods are essential for treating non-union instances and bone fractures. By encouraging bone production and quickening the healing process, the use of bone morphogenetic proteins (BMPs) has completely changed the treatment of fractures [9]. When applied topically or via scaffolds, bone morphogenetic proteins (BMPs) promote osteogenesis, speeding up the healing process and improving fracture union, particularly in severe abnormalities where traditional therapies might not be effective.

Moreover, the use of tissue engineering techniques in orthopaedic medicine has demonstrated potential in managing intricate musculoskeletal ailments. The use of biomimetic scaffolds in bone defect restoration has great promise since they are engineered to resemble natural tissue architecture and offer a favourable milieu for cell proliferation and differentiation [10]. These scaffolds help to promote tissue regeneration and restore the structural integrity of broken bone segments. They are made of different materials and may include growth factors or stem cells.

Additionally, there is promise for regenerative orthopaedic therapies in spinal surgery, namely in spinal fusion operations. In order to achieve effective spinal fusion and lessen the morbidity associated with autograft harvesting, BMPs have been widely employed as alternatives to autologous bone grafts [11]. In order to provide patients undergoing spinal surgeries with favourable results, regenerative techniques are being applied in spine surgery with the goal of improving fusion rates, stabilising spinal segments, and accelerating bone recovery.

The integration of regenerative orthopaedic treatments into standard clinical practice continues to present difficulties, despite these encouraging applications. Careful thought must be given to issues pertaining to treatment standardisation, ideal dosage, and long-term safety assessments [12]. Further impediments to the widespread implementation of these innovative medicines in diverse healthcare settings include their cost and accessibility.

Section 3: Challenges and Limitations in Regenerative Orthopedics

Even though regenerative medicine in orthopaedics offers exciting new treatment options, there are a number of obstacles and restrictions that prevent it from being easily incorporated into clinical practice.

Standardising procedures and methods for all regenerative orthopaedic therapies is one of the main obstacles. The repeatability and effectiveness of these treatments are impacted by discrepancies

introduced by variation in cell source, separation techniques, and administration regimens [9]. It is imperative to establish standard operating procedures and standards in order to guarantee consistency and dependability across various regeneration techniques.

Ensuring the safety and effectiveness of regenerative therapies in the long run is still a major challenge. Comprehensive longitudinal investigations evaluating the durability and potential negative effects are crucial, even if first research demonstrate encouraging short-term results [10]. To assess the durability of therapeutic advantages and to find any possible side effects or unexpected outcomes related to these novel therapies, long-term follow-ups are required.

Regenerative orthopaedics has problems due to ethical questions regarding the use of certain cell sources and treatment techniques. Ethical conundrums are raised by the ethical source of cells, especially embryonic stem cells, which calls for strict adherence to ethical norms and legislation [11]. Furthermore, to guarantee ethical practice and accessibility, concerns about patient permission, privacy, and the fair distribution of these cutting-edge medicines among varied groups need to be carefully considered.

Accessibility and cost-effectiveness continue to be major barriers to the general use of regenerative orthopaedic therapies. There are issues about fairness in healthcare access due to the high prices of these new medicines, which prevent them from being accessible to a larger patient population [12]. It is imperative to tackle the economic ramifications of regenerative therapies and devise tactics to mitigate their price burden in order to guarantee their incorporation into standard clinical practice.

Another obstacle to the smooth incorporation of regenerative orthopaedic therapy is regulatory obstacles. The rapid progress in regenerative medicine sometimes overwhelms current regulatory frameworks, making it more difficult to assure patient safety and streamline approval procedures [13]. Ensuring patient safety and easing the clinical translation of regenerative therapies need harmonising regulatory standards worldwide and expediting approval routes specifically for these interventions.

Furthermore, one of the biggest challenges in the field of regenerative orthopaedics is the teaching and training of medical personnel. Because of the speed at which these novel medicines are developing, healthcare professionals must get ongoing education and training to guarantee their expertise in administering these treatments [14]. Enhancing the uptake and optimal utilisation of regenerative orthopaedic therapies requires closing the knowledge gap through specialised training programmes and ongoing medical education.

Section 4: Ethical Considerations and Regulatory Aspects

To guarantee patient safety, equal access, and ethical practice, the integration of regenerative orthopaedic treatments requires a strong framework that addresses ethical issues and regulatory elements.

A fundamental tenet of the use of regenerative medicine in orthopaedics is ethical considerations. Important considerations include those involving patient permission, privacy, and the moral procurement of cells [13]. In order to enable patients to make educated decisions about their healthcare, informed consent is necessary to guarantee that they are aware of the nature of these cutting-edge therapies, any possible hazards, and the anticipated results. Furthermore, upholding ethical standards in practice necessitates protecting patient privacy and confidentiality while managing sensitive data connected to regenerative treatments.

There is ongoing discussion on the moral source of cells used in regenerative orthopaedic therapies. Because they are not contentious, adult stem cells have ethical advantages, but there are still issues with using embryonic stem cells [14]. Due to the moral ramifications associated with the use of embryonic stem cells, strict adherence to moral standards and laws is required, guaranteeing ethical sourcing and usage practices.

Furthermore, it is morally required to guarantee that a variety of communities have fair access to regenerative orthopaedic therapy. Healthcare disparities already present may be made worse by differences in access to these cutting-edge therapies depending on socioeconomic status [15]. The need to close these gaps and make these cutting-edge treatments available to all patients, regardless of their financial situation, is dictated by ethical concerns.

Regarding regulations, regulatory organisations are essential in monitoring the security, effectiveness, and moral use of regenerative orthopaedic treatments. The regulatory structures that oversee the authorization, production, and medical application of these novel therapies must change to accommodate the distinct characteristics of regenerative medicine [16]. Collaboration between regulatory agencies, researchers, doctors, and industry stakeholders is necessary to strike a balance between promoting innovation and guaranteeing patient safety.

Global regulatory standardisation is a major barrier for the area of regenerative orthopaedics. The approval procedures and marketing of these medicines are complicated by the diverse regulatory

environments that exist across various nations and regions [17]. Globally standardised guidelines and shortened approval processes tailored to regenerative interventions are essential for promoting cross-border cooperation, guaranteeing uniformity in safety assessments, and hastening the development of these treatments for the benefit of patients everywhere.

Furthermore, it is imperative to guarantee post-market surveillance and ongoing monitoring of regenerative orthopaedic treatments in order to evaluate their enduring safety and effectiveness [18]. In order to continue improving safety and patient care, robust pharmacovigilance systems are essential for identifying and managing any adverse events or unexpected outcomes connected to these developing medications.

In addition, it is imperative to promote multidisciplinary cooperation among regulatory agencies, physicians, researchers, ethicists, and patient advocacy organisations to effectively navigate the intricate ethical and regulatory terrain of regenerative orthopaedics [19]. These kinds of partnerships make it easier to create thorough rules, instructional programmes, and policy frameworks that comply with moral standards and legal obligations.

Section 5: Future Perspectives and Conclusion

With revolutionary developments that have the potential to completely alter orthopaedic treatment and patient outcomes, the field of regenerative orthopaedics has a bright future ahead of it. In order to advance the field towards its maximum potential, a few crucial issues need to be addressed going forward.

The incorporation of advanced technologies, including machine learning and artificial intelligence (AI), is expected to play a significant role in regenerative orthopaedics' future developments [17]. Artificial intelligence (AI)-powered algorithms have the capacity to evaluate enormous datasets, forecast patient reactions to treatments, and customise therapeutic strategies, enabling precision medicine in orthopaedics. In order to provide a more individualised and successful approach to patient care, machine learning models can help with treatment protocol optimisation, therapeutic outcome prediction, and identification of patient-specific variables impacting the efficacy of regenerative therapies.

Moreover, new potential in tissue engineering and scaffold manufacturing are presented by the confluence of sophisticated biomaterials, 3D printing technologies, and regenerative medicine [18]. Advancements in biomaterials design and biofabrication methodologies allow the production of highly adaptable and patient-specific scaffolds that more closely resemble the original tissue microenvironment. Enhanced tissue regeneration can be achieved by developing bioactive scaffolds with precise control over scaffold design, porosity, and mechanical qualities, made possible by 3D printing technology.

The advent of customised regenerative therapies signifies a change in perspective towards individualised care that takes patient variability into consideration [19]. The thorough characterization of biological profiles particular to each patient is made possible by advancements in omics technologies, including transcriptomics, proteomics, and genomes. By identifying indicators for therapy response, developing personalised regeneration techniques, and choosing the best cell sources, this personalised strategy eventually improves patient outcomes and treatment efficacy.

Transforming scientific discoveries into practical applications and fostering innovation depend heavily on interdisciplinary cooperation between academics, doctors, engineers, and bioethicists [20]. Joint endeavours cultivate mutually beneficial relationships, utilising a range of specialised knowledge to tackle intricate problems and expedite the conversion of benchtop findings into clinical applications. By incorporating different points of view, holistic ways to addressing the complex issues of regenerative orthopaedics may be developed, opening the door to more thorough and efficient therapies.

To sum up, regenerative orthopaedics has a bright future ahead of it, one marked by multidisciplinary cooperation, personalised treatment plans, and technology breakthroughs. Orthopaedic care is about to undergo a revolution because to the confluence of AI, cutting-edge biomaterials, personalised medicine, and cooperative efforts. These innovations will enable customised, efficient, and patient-centered care.

Realising the full promise of regenerative orthopaedics will depend critically on the unwavering pursuit of innovation, ethical practice, and regulatory adherence—even in the face of ongoing challenges and obstacles. Through adept handling of these obstacles, adoption of cutting-edge technology, establishment of cooperative alliances, and emphasis on patient-centered treatment, the sector is positioned for revolutionary expansion, guaranteeing better patient outcomes and elevated quality of life.

REFERENCES

1. Voga, M., & Majdic, G. (2022). Articular Cartilage Regeneration in Veterinary Medicine. Advances in Experimental Medicine and Biology, 1401, 23-55. doi: 10.1007/5584_2022_717. PMID: 35733035.

2. Nair, M. A., Shaik, K. V., Kokkiligadda, A., & Gorrela, H. (2020). Tissue-engineered Maxillofacial Skeletal Defect Reconstruction by 3D Printed Beta-tricalcium phosphate Scaffold Tethered with Growth Factors and Fibrin Glue Implanted Autologous Bone Marrow-Derived Mesenchymal Stem Cells. Journal of Medicine and Life, 13(3), 418-425. doi: 10.25122/jml-2020-0044. PMID: 33072218; PMCID: PMC7550144.
3. Danilkowicz, R., Murawski, C., Pellegrini, M., Walther, M., Valderrabano, V., Angthong, C., ... Adams, S. (2022). Nonoperative and Operative Soft-Tissue and Cartilage Regeneration and Orthopaedic Biologics of the Foot and Ankle: An Orthoregeneration Network Foundation Review. Arthroscopy, 38(7), 2350-2358. doi: 10.1016/j.arthro.2022.04.018. PMID: 35605840.
4. Migliorini, F., Tingart, M., & Maffulli, N. (2020). Progress with stem cell therapies for tendon tissue regeneration. Expert Opinion on Biological Therapy, 20(11), 1373-1379. doi: 10.1080/14712598.2020.1786532. PMID: 32574078.
5. Condron, N. B., Kester, B. S., Tokish, J. M., Zumstein, M. A., Gobezie, R., Scheibel, M., & Cole, B. J. (2021). Nonoperative and Operative Soft-Tissue, Cartilage, and Bony Regeneration and Orthopaedic Biologics of the Shoulder: An Orthoregeneration Network (ON) Foundation Review. Arthroscopy, 37(10), 3200-3218. doi: 10.1016/j.arthro.2021.06.033. PMID: 34293441.
6. Li, Z., Wu, N., Cheng, J., Sun, M., Yang, P., Zhao, F., ... Ao, Y. (2020). Biomechanically, structurally and functionally meticulously tailored polycaprolactone/silk fibroin scaffold for meniscus regeneration. Theranostics, 10(11), 5090-5106. doi: 10.7150/thno.44270. PMID: 32308770; PMCID: PMC7163455.
7. Veronesi, F., Martini, L., Giavaresi, G., & Fini, M. (2020). Bone regenerative medicine: metatarsus defects in sheep to evaluate new therapeutic strategies for human long bone defect. A systematic review. Injury, 51(7), 1457-1467. doi: 10.1016/j.injury.2020.04.010. PMID: 32430197.
8. Hernigou, J., Vertongen, P., Rasschaert, J., & Hernigou, P. (2021). Role of Scaffolds, Subchondral, Intra-Articular Injections of Fresh Autologous Bone Marrow Concentrate Regenerative Cells in Treating Human Knee Cartilage Lesions: Different Approaches and Different Results. International Journal of Molecular Sciences, 22(8), 3844. doi: 10.3390/ijms22083844. PMID: 33917689; PMCID: PMC8068069.
9. Muttigi, M. S., Kim, B. J., Choi, B., Han, I., Park, H., & Lee, S. H. (2020). Matrilin-3-Primed Adipose-Derived Mesenchymal Stromal Cell Spheroids Prevent Mesenchymal Stromal-Cell-Derived Chondrocyte Hypertrophy. International Journal of Molecular Sciences, 21(23), 8911. doi: 10.3390/ijms21238911. PMID: 33255398; PMCID: PMC7727796.
10. Liebig, B. E., Kisiday, J. D., Bahney, C. S., Ehrhart, N. P., & Goodrich, L. R. (2020). The platelet-rich plasma and mesenchymal stem cell milieu: A review of therapeutic effects on bone healing. Journal of Orthopaedic Research, 38(12), 2539-2550. doi: 10.1002/jor.24786. PMID: 32589800; PMCID: PMC8354210.
11. Vasanthan, J., Gurusamy, N., Rajasingh, S., Sigamani, V., Kirankumar, S., Thomas, E. L., ... Rajasingh, J. (2020). Role of Human Mesenchymal Stem Cells in Regenerative Therapy. Cells, 10(1), 54. doi: 10.3390/cells10010054. PMID: 33396426; PMCID: PMC7823630.
12. Johnstone, B., Stoddart, M. J., & Im, G. I. (2020). Multi-Disciplinary Approaches for Cell-Based Cartilage Regeneration. Journal of Orthopaedic Research, 38(3), 463-472. doi: 10.1002/jor.24458. PMID: 31478253.
13. Zhang, M., Matinlinna, J. P., Tsoi, J. K. H., Liu, W., Cui, X., Lu, W. W., & Pan, H. (2019). Recent developments in biomaterials for long-bone segmental defect reconstruction: A narrative overview. Journal of Orthopaedic Translation, 22, 26-33. doi: 10.1016/j.jot.2019.09.005. PMID: 32440496; PMCID: PMC7231954.
14. Li, S., Liu, P., Zhu, T., Sui, B., Jin, Y., Xuan, K., ... Zheng, C. (2023). Construction, Characterization, and Regenerative Application of Self-Assembled Human Mesenchymal Stem Cell Aggregates. Journal of Visualized Experiments, (193). doi: 10.3791/64697. PMID: 37036220.
15. Maqsood, M., Kang, M., Wu, X., Chen, J., & Teng, L. (2020). Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine. Life Sciences, 256, 118002. doi: 10.1016/j.lfs.2020.118002. PMID: 32585248.
16. Shen, H., Lin, H., Sun, A. X., Song, S., Wang, B., Yang, Y., ... Tuan, R. S. (2020). Acceleration of chondrogenic differentiation of human mesenchymal stem cells by sustained growth factor release in 3D graphene oxide incorporated hydrogels. Acta Biomaterialia, 105, 44-55. doi: 10.1016/j.actbio.2020.01.048. PMID: 32035282.
17. Su, X., Wang, T., & Guo, S. (2021). Applications of 3D printed bone tissue engineering scaffolds in the stem cell field. Regenerative Therapy, 16, 63-72. doi: 10.1016/j.reth.2021.01.007. PMID: 33598507; PMCID: PMC7868584.
18. Oryan, A., Hassanajili, S., Sahvieh, S., & Azarpira, N. (2020). Effectiveness of mesenchymal stem cell-seeded onto the 3D polylactic acid/polycaprolactone/hydroxyapatite scaffold on the radius bone defect in rat. Life Sciences, 257, 118038. doi: 10.1016/j.lfs.2020.118038. PMID: 32622947.
19. Militello, G., & Bertolaso, M. (2022). Stem Cells and the Microenvironment: Reciprocity with Asymmetry in Regenerative Medicine. Acta Biotheoretica, 70(4), 24. doi: 10.1007/s10441-022-09448-0. PMID: 35962861.
20. Roseti, L., & Grigolo, B. (2022). Current concepts and perspectives for articular cartilage regeneration. Journal of Experimental Orthopaedics, 9(1), 61. doi: 10.1186/s40634-022-00498-4. PMID: 35776217; PMCID: PMC9249961.